Defymed is a French SME that develops innovative medical devices aimed at treating patients physiologically in order to improve the clinical effectiveness of their treatment as well as their comfort. Defymed is a spin-off of the Centre européen d’étude du Diabète (European center for diabetes studies), which began work on a bioartificial pancreas in 1996. Today, Defymed focuses on diabetes, which is considered to be one of the major epidemics of the 21st century. There are currently two medical devices being developed by Defymed which are at an advanced preclinical trial phase: - #MailPan®: bioartificial pancreas - #ExOlin®: physiological insulin delivery device